12 completed, 7 terminated, 4 recruiting, 1 no longer available. 8 Phase 2, 8 Phase 3, 4 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Terminated 1 |
| Phase 3 | 8 | Completed 5, Terminated 2, Recruiting 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Phase 4 | 3 | Terminated 2, Completed 1 |
Follow sotrovimab: new trials by email Literature Review of sotrovimab trials Research Report on sotrovimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19 Sotrovimab - COVID-19 | Phase 4 | Completed | GlaxoSmithKline | 217 | 2022-07-01 | 2026-10-06 |
| Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain Sotrovimab - COVID-19 | Unknown | Abu Dhabi Health Services Company | 20000 | 2022-05-12 | 2022-06-01 | |
| Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) sotrovimab - Covid19 | Phase 1 | Terminated | Vir Biotechnology, Inc. | 316 | 2022-03-28 | 2024-09-19 |
| Non-inferiority Trial on Treatments in Early COVID-19 Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir - COVID-19 | Phase 3 | Completed | Azienda Ospedaliera Universitaria Integrata Verona | 536 | 2022-03-07 | 2023-11-07 |
| A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals Sotrovimab - SARS CoV 2 Infection | Phase 2 | Completed | Sophia Koo, M.D. | 93 | 2022-02-07 | 2024-08-15 |
| Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study Questionnaire Administration, Sotrovimab, Biospecimen Collection - COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 20 | 2022-01-25 | 2025-02-13 |
| Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 Sotrovimab - COVID-19 | Phase 2 | Terminated | GlaxoSmithKline | 8 | 2021-12-16 | 2024-01-03 |
| TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 casirivimab with imdevimab, sotrovimab, molnupiravir - COVID-19 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1178 | 2021-12-14 | 2025-12-16 | |
| Non-inferiority Trial on Monoclonal Antibodies in COVID-19 Bamlanivimab Etesevimab, Sotrovimab, Casirivimab-Imdevimab - COVID-19 | Phase 3 | Terminated | Azienda Ospedaliera Universitaria Integrata Verona | 319 | 2021-12-09 | 2022-07-26 |
| COVID-19 International Drug Pregnancy Registry Antiviral Agents, Monoclonal antibody - Covid19 | Recruiting | Pregistry | 2000 | 2021-12-01 | 2025-09-26 | |
| COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 Bamlanivimab, Bamlanivimab and Etesevimab Drug Combination, Casirivimab and Imdevimab Drug Combination - COVID-19 | Completed | University of Milano Bicocca | 251 | 2021-10-14 | 2025-03-30 | |
| Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™) - COVID-19 | Phase 2 | Recruiting | University of Oxford | 3800 | 2021-09-30 | 2026-02-19 |
| A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants sotrovimab, Placebo to Biologic - Covid19 | Phase 1 | Completed | Vir Biotechnology, Inc. | 48 | 2021-07-06 | 2024-06-07 |
| Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. sotrovimab, Sotrovimab - Covid19 | Phase 3 | Terminated | Vir Biotechnology, Inc. | 1065 | 2021-06-10 | 2024-03-07 |
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V Niclosamide, Placebo, Ciclesonide - Covid19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 2240 | 2021-02-19 | 2025-06-20 |
| Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 Sotrovimab (Gen1), Sotrovimab (Gen2) - Covid19 | Phase 2 | Completed | Vir Biotechnology, Inc. | 354 | 2021-02-18 | 2023-05-03 |
| Treatment of Nosocomial COVID-19 Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection | Phase 4 | Terminated | University of Calgary | 46 | 2021-02-12 | 2023-04-19 |
| VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) VIR-7831, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 367 | 2020-12-16 | 2023-12-27 |
| A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Bamlanivimab, Etesevimab, Placebo - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 1755 | 2020-10-29 | 2022-07-01 |
Showing 20 of 25. Sign in to see all of them.
COVID-19 (25) · Coronavirus Infections (8) · Coronaviridae Infections (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2) · Community-Acquired Pneumonia (1) · Cross Infection (1) · Glomerulonephritis (1) · Hematologic Neoplasms (1) · Lupus Erythematosus, Systemic (1) · Neoplasms (1) · Pneumonia (1) · Vasculitis (1)
Vir Biotechnology, Inc. (6) · Azienda Ospedaliera Universitaria Integrata Verona (2) · GlaxoSmithKline (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Oxford (2) · Abu Dhabi Health Services Company (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Eli Lilly and Company (1) · Erin McCreary (1) · Fred Hutchinson Cancer Center (1) · Pregistry (1) · Sophia Koo, M.D. (1) · University of Calgary (1) · University of Liverpool (1)
United States (14) · United Kingdom (7) · Italy (5) · Spain (5) · Canada (3) · Brazil (2) · Denmark (2) · France (2) · Nepal (2) · Netherlands (2) · Poland (2) · Singapore (2) · South Africa (2) · Switzerland (2) · Uganda (2)
Alain Tremblay (1) · Alpana Waghmare (1) · Cheryl Renz, MD (1) · David T Huang, MD, MPH (1) · Erin McCreary, PharmD (1) · James Neaton, Prof. (1) · Jennifer Manne-Goehler, MD, ScD (1) · Jens Lundgren, Prof. (1) · Paolo Bonfanti, MD (1) · Peter W Horby (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1) · Robert Fowler (1)
PMID 34473343, PMID 35713300, PMID 34928698, PMID 32678530, PMID 33031652, PMID 33031764, PMID 33356051, PMID 33394942, PMID 33545096, PMID 33933206, PMID 34000257, PMID 34013969, PMID 34034784, PMID 34374951, PMID 34450619, PMID 34658014, PMID 34672950, PMID 34699618, PMID 34706189, PMID 34800427, PMID 34953520, PMID 35151397, PMID 35271729, PMID 35285853, PMID 35298440, PMID 35695334, PMID 35697146, PMID 35817072, PMID 35834252, PMID 35908569, PMID 35913747, PMID 35939810, PMID 35977462, PMID 36272432, PMID 36413383, PMID 36435798, PMID 36522698, PMID 36703019, PMID 36734509, PMID 36803992, PMID 36915199, PMID 37060915, PMID 37162745, PMID 37328890, PMID 37410460, PMID 37470445, PMID 37489818, PMID 37520411, PMID 37577112, PMID 37702920